Johnson & Johnson has agreed to acquire Novira Therapeutics for an undisclosed sum, providing an exit to WuXi PharmaTech, an investor in its $28m series A round.

The Novartis-backed eye disease therapy developer set the range last month for an initial public offering sized at up to $65m.

San Diego spinout Biological Dynamics secures $26.8m in series C backed by large institutional investor.

Biogen has co-led a $42.5m series B round for the developer of treatments for muscular dystrophy.

Fidelity-backed biopharmaceutical company Kura floated on Nasdaq yesterday and will use proceeds to fund clinical trials.

The therapeutic antibodies developer has closed its series A round backed by GlaxoSmithKline.

The oversubscribed fund has been backed by a range of unnamed insurance companies.